Meeting
2014 ASCO Annual Meeting
A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.
Authors
Konstantinos Tryfonidis
EORTC Headquarters, Brussels, Belgium
Konstantinos Tryfonidis , Jan Bogaerts , Robert E. Martell , George W. Sledge , Judith Balmaña , M. William Audeh , Angelique Deleersnijder , Felicia Favorito , Shefali Agarwal , Giovanna Rizzetto , Carlo G. M. Messina , Leen Slaets , Theodora Goulioti , Andrew Tutt , David A. Cameron , Nicholas C. Turner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01905592
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS659)
DOI
10.1200/jco.2014.32.15_suppl.tps659
Abstract #
TPS659
Poster Bd #
119B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).
First Author: Hope S. Rugo
Poster
2022 ASCO Annual Meeting
Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.
First Author: Aditya Bardia
Poster
2015 ASCO Annual Meeting
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
First Author: Jennifer Keating Litton